Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer

Park, Henry S.; Harder, E.; Mancini, B.R.; Decker, Roy H.

doi:10.1097/jto.0000000000000484

Cited by 73 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One phase 3 study comparing SBRT and surgery (only the SBRT data was used) [12], 10 phase 2 [20-31], 1 phase 1 [32], and 56 retrospective [33-51,53-89] photon SBRT studies were included in the survival outcome comparison analysis. Among them, treatment-related toxicities were reported in all the prospective studies [12,20-32], and 40 retrospective studies [34,37,39-40,42,44-47,49,52-61,65,67-73,76-78, 80-82,84-89]. These studies were included in the treatment-related toxicity comparison analysis.…”

Section: Resultsmentioning

confidence: 99%

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

Chi¹,

Chen

Wen

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

Purpose To assess hypo-fractionated particle beam therapy (PBT)'s efficacy relative to that of photon stereotactic body radiotherapy (SBRT) for early stage (ES) non-small cell lung cancer (NSCLC). Methods Eligible studies were identified through extensive searches of the PubMed, Medline, Google-scholar, and Cochrane library databases from 2000 to 2016. Original English publications of ES NSCLC were included. A meta-analysis was performed to compare the survival outcome, toxicity profile, and patterns of failure following each treatment. Results 72 SBRT studies and 9 hypo-fractionated PBT studies (mostly single-arm) were included. PBT was associated with improved overall survival (OS; p = 0.005) and progression-free survival (PFS; p = 0.01) in the univariate meta-analysis. The OS benefit did not reach its statistical significance after inclusion of operability into the final multivariate meta-analysis (p = 0.11); while the 3-year local control (LC) still favored PBT (p = 0.03). Conclusion Although hypo-fractionated PBT may lead to additional clinical benefit when compared with photon SBRT, no statistically significant survival benefit from PBT over SBRT was observed in the treatment of ES NSCLC in this hypothesis-generating meta-analysis after adjusting for potential confounding variables.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

Chi¹,

Chen

Wen

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…On the other hands, there are some different reports about SBRT. One has been reported that tumor location was not associated with worse prognosis for patients treated with SBRT, 40 and the other has been reported central tumors increased risk of high-grade toxicity or death. 41 Lebioda et al 42 reported that the risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes was significantly high for central tumor location.…”

Section: Discussionmentioning

confidence: 98%

Prognostic Value of Semiautomatic CT Volumetry in Patients With Stage I Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy

Satoh

Nambu²,

Saito³

et al. 2016

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

show abstract

“…Patients meeting all inclusion criteria underwent chart review for type of oncologic treatment, clinical outcome, and MAC treatment regimen. Additionally, chest imaging from initial lung cancer diagnosis was reviewed, when available, and tumors were classified as central if they were within 2 cm of the proximal bronchial tree or other mediastinal structures [14].…”

Section: Methodsmentioning

confidence: 99%

Characteristics of Mycobacterium avium complex (MAC) pulmonary disease in previously treated lung cancer patients

Meier

Pennington

Moraes

et al. 2017

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

IntroductionMycobacterium avium complex (MAC) is responsible for a large portion of non-tuberculous mycobacterial (NTM) infections worldwide. Host factors such as active malignancy, immunosuppression, chronic obstructive pulmonary disease (COPD) and bronchiectasis increase the risk of MAC infection. However, the relationship between previously treated lung cancer with subsequent development of MAC pulmonary disease and treatment outcomes have not been previously studied.MethodsWe retrospectively identified all patients with lung cancer and MAC pulmonary disease documented in medical records at Mayo Clinic between January 2005 and October 2016. Patients who were diagnosed with MAC pulmonary disease before or at the time of lung cancer diagnosis were excluded. Patients meeting all inclusion criteria underwent chart review for prior oncologic treatments, clinical characteristics, and MAC treatment response.ResultsWe identified 13 patients with MAC pulmonary disease and prior lung cancer, including 4 men and 9 women. Eight patients had structural lung disease that can predispose to MAC pulmonary disease, including bronchiectasis (23.0%) and COPD (46.2%). Four (30.8%) had no apparent immunosuppression or other risk factor(s) for MAC pulmonary disease. Primary pulmonary malignancies included pulmonary carcinoid, adenocarcinoma, and squamous cell carcinoma. Ten (76.9%) patients were started on antimicrobial treatment for MAC, and 8 (61.5%) patients completed MAC treatment with 6 (46.1%) patients achieving symptomatic improvement.ConclusionMAC pulmonary disease in previously treated lung cancer can occur without apparent risk factors for this NTM infection. Symptomatic improvement with MAC antimicrobial therapy appears to be lower than expected but comorbidities might influence outcomes in this patient population.

show abstract

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer

Abstract: Central tumor location did not predict for inferior OS, LC, or toxicity following SBRT when a lower mean BED was utilized.

Cited by 73 publications

References 17 publications

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

Prognostic Value of Semiautomatic CT Volumetry in Patients With Stage I Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy

Characteristics of Mycobacterium avium complex (MAC) pulmonary disease in previously treated lung cancer patients

Contact Info

Product

Resources

About